查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球硬皮病市场
市场调查报告书
商品编码
1272773

2023-2030 年全球硬皮病市场

Global Scleroderma Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球硬皮病市场预计到 2022 年将达到 21.694 亿美元，到 2030 年将达到 34.683 亿美元。 预计硬皮病市场在预测期内（2023-2030 年）的复合年增长率为 6.2%。 主要市场参与者正在采取各种战略，包括产品批准、收购、合作伙伴关係和新推出，以扩大产品范围并加强产品组合，以进入硬皮病市场或扩大其业务范围，以增强竞争力。

例如，2022 年 3 月 11 日，辉瑞公司收购了 Arena Pharmaceuticals，这是一家临床阶段的公司，开髮用于治疗多种免疫炎症性疾病的创新潜在疗法。 Arena 的管道包括两个开发心血管资产，用于微血管闭塞的替莫格雷和继发于系统性硬化症的雷诺现象，以及用于急性心力衰竭的 APD418。

硬皮病是一种自身免疫性结缔组织和风湿性疾病，可引起皮肤和身体其他器官的炎症。 虽然是一种罕见疾病，但其侵袭性和日益流行等因素正在推动全球硬皮病市场的增长。

市场动态

研究资金和投资预计将在预测期内推动硬皮病市场的增长

硬皮病治疗研究的资金和投资活动不断增加，预计将在预测期内推动全球硬皮病市场的发展。 例如，国家硬皮病基金会能够在 2022 年获得研究资助，将研究经费增加一倍，达到 240 万美元。 此外，2023 年 2 月，美国国家硬皮病基金会宣布每年拨款 160 万美元，用于支持硬皮病新疗法的鑑定和设计。

增加对抗硬皮病的举措提供市场增长机会

为提高认识和为硬皮病患者提供支持的举措越来越多，这为未来几年的全球硬皮病市场带来了有利可图的增长机会。 例如，2023 年 1 月，为未投保的美国人提供经济生命线的自治非营利组织 Healthwell 基金会宣布，系统性硬化症伴间质性肺病 (SSc -ILD) 扩大了一项新预算，为 ILD 患者提供经济援助。 通过新的预算，HealthWell 打算为家庭年收入高达联邦贫困线 500% 的患者提供高达 9,000 美元的共同支付或疾病管理保费援助。

俄乌衝突分析

俄乌衝突对市场产生了不利影响，许多研究因衝突造成的情况而被推迟，直接影响了全球硬皮病市场的增长。 例如，根据 2022 年 4 月发表的一篇新文章，俄罗斯与乌克兰的战争导致医生急于将流离失所的患者运送到未开发的治疗中心，促使罗氏控股 AG 的多发性硬化症治疗药物的最新试验受到影响。

全球经济衰退影响分析

医疗保健行业也不能完全免受衰退的影响。 但由于其固有的性质，它比其他行业处理得更好。 然而，随着通胀继续上升，经济衰退危机威胁着市场。 持续的经济衰退导致的紧张局势加剧可能会对未来几年的硬皮病市场产生重大影响。

人工智能影响分析

人工智能在硬皮病诊断和治疗方面的前景优势预计将对全球硬皮病市场产生积极影响。 例如，根据美国风湿病学会 ACR Convergence 2022 年会上提出的结论，开源计算机算法 Vision Transformer (ViT) 能够捕捉到指甲毛细血管 (NFC) 异常的照片。。

内容

第 1 章研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按治疗方法
  • 按疾病类型
  • 最终用户
  • 按地区

第四章市场动态

  • 影响因素
    • 主持人
      • 增加产品批准
      • 增加筹款和投资
    • 约束因素
      • 药物的副作用
    • 机会
      • 提高认识
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第七章俄乌衝突分析

第八章全球经济衰退分析

第9章人工智能的影响分析

第10章治疗

  • 药物治疗
    • 免疫抑製剂
    • 磷酸二酯□ 5 抑製剂-PHA
    • 内皮素受体拮抗剂 (ERA)
    • 钙通道阻滞剂 (CCB)
    • 前列环素类似物 (PA)
    • 止痛药
    • 其他
  • 手术和其他治疗

第 11 章按疾病类型分类

  • 系统性硬化症
    • 局限性皮肤系统性硬化症
    • 瀰漫性系统性硬化症
    • 信号硬化
  • 局部硬皮病
    • 吗啡
    • 线状硬皮病

第 12 章最终用户

  • 医院
  • 零售/在线药店
  • 其他

第13章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第14章竞争格局

  • 竞争场景
  • 市场份额分析
  • 併购分析

第十五章公司简介

  • 辉瑞公司
    • 公司概况
    • 产品组合和说明
    • 财务摘要
    • 主要发展状况
  • Sanofi
  • GlaxoSmithKline plc
  • Cumberland Pharmaceuticals, Inc.
  • Actelion Pharmaceuticals, Inc.（Johnson & Johnson）
  • Boehringer Ingelheim International GmbH（C.H. Boehringer Sohn Ag & Co. KG）
  • Corbus Pharmaceuticals Holdings, Inc.
  • Bayer AG
  • Gilead Sciences, Inc.
  • Allergan, Inc.（Abbvie）

第16章 附录

简介目录
Product Code: PH1221

Market Overview

The global scleroderma market reached USD 2,169.4 million in 2022 and is projected to witness to reach up to USD 3,468.3 million by 2030. The scleroderma market is expected to exhibit a CAGR of 6.2% during the forecast period (2023-2030). The key market players are adopting various strategies such as product approvals, acquisitions, partnerships, and new launches to increase product reach and strengthen their product portfolios, to enter or expand their business offerings and competitiveness in the scleroderma market.

For instance, on March 11, 2022, Pfizer Inc. completed its acquisition of Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies for treating several immuno-inflammatory diseases. Arena's pipeline includes two development-stage cardiovascular assets: temanogrel for microvascular obstruction and Raynaud's phenomenon secondary to systemic sclerosis and APD418 for acute heart failure.

Scleroderma is an autoimmune connective tissue and rheumatic disorder that induces inflammation in the skin and other organs of the body. Though it is a rare disorder, the aggressive nature and growing prevalence among other factors are boosting the global scleroderma market growth.

Market Dynamics

The research funding and investments are expected to drive the scleroderma market growth during the forecast period

The increasing funding and investment activities for scleroderma treatment research are expected to boost the global scleroderma market over the forecast period. For instance, the National Scleroderma Foundation secured research grants in 2022, allowing double their research funding to USD 2.4 million. Additionally, in February 2023, the National Scleroderma Foundation announced its annual grant awards totaling USD 1.6 million to support identifying and designing new treatments and a cure for scleroderma.

The growing initiatives in the fight against scleroderma provide the market with growth opportunities

The increasing initiatives to spread awareness and provide support to scleroderma patients are presenting the global scleroderma market with lucrative growth opportunities in the forthcoming years. For instance, in January 2023, the HealthWell Foundation, an autonomous non-profit organization that delivers a financial lifeline for poorly insured Americans, extended a new budget to deliver financial help to individuals living with systemic sclerosis with interstitial lung disease (SSc-ILD). Via the new budget, HealthWell intends to deliver up to USD 9,000 in medication copayment or insurance premium subsidy to suitable patients with annual family earnings up to 500% of the federal poverty level for managing their disorder.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war has negatively impacted the market and because of the conflict-induced situation, many research studies have been delayed directly impacting the global scleroderma market growth. For instance, according to a new article published in April 2022, Russia's war in Ukraine has affected trials of Roche Holding AG's latest testing of multiple sclerosis medication, as physicians rush to transfer patients who have become refugees to unexplored treatment bases.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession could hold a substantial influence on the scleroderma market over the following few years.

Artificial Intelligence Impact Analysis

The perspective benefits offered by AI in scleroderma diagnosis and treatment are estimated to have a positive influence on the global scleroderma market. For instance, the open-source computer algorithm Vision Transformer (ViT) could catch anomalies on nail fold capillaroscopy (NFC) pictures, according to conclusions submitted at the annual meeting of the American College of Rheumatology ACR Convergence 2022.

Segment Analysis

The global scleroderma market is segmented based on treatment, disease type, end users, and region.

The systemic sclerosis segment is estimated to hold the largest global scleroderma market share by 2030

Owing to the growing cases and new drug approvals, systemic sclerosis segment is estimated to hold a market share of around 74.6% of the entire scleroderma market by 2030. For instance, according to the University of Michigan Health, systemic sclerosis occurs in around 30 persons per million population per year and there are an estimated 125,000 active cases in the U.S. and perhaps 2.5 million worldwide. It is the most fatal of all rheumatologic diseases. Also, in April 2022, aTyr Pharma, Inc., a public biotherapeutics company obtained USFDA clearance for efzofitimod utilized in the treatment of systemic sclerosis.

Geographical Analysis

Europe is estimated to hold the second-largest share of the global scleroderma market during the forecast period

Owing to the presence of a better action plan and its execution in this region for the scleroderma condition, the Europe region is estimated to hold about 27.6% of the global scleroderma market by 2030. For instance, over the duration of 2022, the England Rare Diseases Framework Delivery Group has persisted to assemble regularly to harmonize the delivery of England's action strategies. The group gets together publicly supported delivery members and agents of the rare condition patient and clinician communities, to observe the delivery of existing commitments, and settle on the scope of prospective action strategies.

Competitive Landscape

The major global players in the market include Pfizer, Inc., Sanofi, GlaxoSmithKline plc, Cumberland Pharmaceuticals, Inc., Actelion Pharmaceuticals, Inc. (Johnson&Johnson), Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG), Corbus Pharmaceuticals Holdings, Inc., Bayer AG, Gilead Sciences, Inc. and Allergan, Inc. (Abbvie) are among others.

Why Purchase the Report?

  • To visualize the global scleroderma market segmentation based on product, application, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of scleroderma market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global scleroderma market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment
  • 3.2. Snippet by Disease Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Product Approvals
      • 4.1.1.2. Increasing Fundings and Investments
    • 4.1.2. Restraints
      • 4.1.2.1. Drug Side Effects
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing Awareness
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Treatment

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.1.2. Market Attractiveness Index, By Treatment
  • 10.2. Medication
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 10.2.3. Immunosuppressors
    • 10.2.4. Phosphodiesterase 5 Inhibitors - PHA
    • 10.2.5. Endothelin Receptor Antagonists (ERA)
    • 10.2.6. Calcium Channel Blockers (CCBs)
    • 10.2.7. Prostacyclin Analogues (PA)
    • 10.2.8. Analgesics
    • 10.2.9. Others
  • 10.3. Surgery & Other Therapies

11. By Disease Type

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.1.2. Market Attractiveness Index, By Disease Type
  • 11.2. Systemic scleroderma*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 11.2.3. Limited Cutaneous Systemic Sclerosis Syndrome
    • 11.2.4. Diffuse Systemic Sclerosis
    • 11.2.5. Sine Sclerosis
  • 11.3. Localized scleroderma
    • 11.3.1. Morphea
    • 11.3.2. Linear Scleroderma

12. By End User

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.1.2. Market Attractiveness Index, By End User
  • 12.2. Hospitals*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Retail and Online Pharmacies
  • 12.4. Others

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.6.1. The U.S.
      • 13.2.6.2. Canada
      • 13.2.6.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.6.1. Germany
      • 13.3.6.2. The U.K.
      • 13.3.6.3. France
      • 13.3.6.4. Italy
      • 13.3.6.5. Spain
      • 13.3.6.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.6.1. Brazil
      • 13.4.6.2. Argentina
      • 13.4.6.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.6.1. China
      • 13.5.6.2. India
      • 13.5.6.3. Japan
      • 13.5.6.4. Australia
      • 13.5.6.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Pfizer, Inc.*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Sanofi
  • 15.3. GlaxoSmithKline plc
  • 15.4. Cumberland Pharmaceuticals, Inc.
  • 15.5. Actelion Pharmaceuticals, Inc. (Johnson & Johnson)
  • 15.6. Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG)
  • 15.7. Corbus Pharmaceuticals Holdings, Inc.
  • 15.8. Bayer AG
  • 15.9. Gilead Sciences, Inc.
  • 15.10. Allergan, Inc. (Abbvie)

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us